Position in ENLV
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$101,158
-$35,005 QoQ
Shares Held
12,262
+25.6% QoQ
Ownership
0.070%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#4
of 25 holders
Holding Since
Jun 2020
5 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ENLV Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026TWO SIGMA INVESTMENTS, LP holds $7,283,390,440 across 343 Biotechnology names. ENLV ranks #314 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
1,875,937 | $564,713,315 | |
| 2 | MRNA |
Moderna, Inc.
|
7,193,530 | $503,762,905 | |
| 3 | IONS |
Ionis Pharmaceuticals Inc
|
6,252,342 | $495,748,197 | |
| 4 | REGN |
Regeneron Pharmaceuticals, Inc.
|
656,124 | $409,119,558 | |
| 5 | BBIO |
BridgeBio Pharma, Inc.
|
4,722,185 | $351,708,338 | |
| 6 | EXEL |
Exelixis, Inc.
|
4,209,861 | $229,058,537 | |
| 7 | INCY |
Incyte Corp
|
2,003,559 | $227,123,448 | |
| 8 | ARGX |
Argenx SE
|
185,638 | $172,229,367 |
All Filings in ENLV
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $101,158 | 183,924 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $136,163 | 146,412 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $137,173 | 195,126 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $11,168 | 10,739 | Shares | Sole | 2025-11-14 | |
| 2020-06-30 | $55,513 | 10,971 | Shares | Sole | 2020-08-14 | |
| No filing history on record for this holder in this stock. | ||||||